Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial

Objective: To explore the effect and safety of avatrombopag for chemotherapy-induced thrombocytopenia (CIT). Methods: This multicenter, open-label, single-arm trial enrolled CIT patients in eight centers from October 2020 to April 2021. The participants received avatrombopag tablets 60 mg once a day...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yayun, He, Yifu, Hu, Changlu, Tu, Congyin, Huang, Jin, Zhu, Xiaofeng, Zang, Chunbao, Ding, Kaiyang, Zhan, Bihong, Zhao, Yufei, Qian, Liting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553127/
https://www.ncbi.nlm.nih.gov/pubmed/36238568
http://dx.doi.org/10.3389/fphar.2022.970978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553127/
https://www.ncbi.nlm.nih.gov/pubmed/36238568
http://dx.doi.org/10.3389/fphar.2022.970978

Ejemplares similares